LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of “Moderate Buy” by Brokerages

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) have received a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $28.80.

LENZ has been the topic of several recent analyst reports. Citigroup restated a “buy” rating on shares of LENZ Therapeutics in a research note on Wednesday, August 12th. Piper Sandler lowered their target price on shares of LENZ Therapeutics from $12.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 12th. Zacks Research upgraded shares of LENZ Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Weiss Ratings cut shares of LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 9th. Finally, HC Wainwright restated a “buy” rating on shares of LENZ Therapeutics in a research note on Tuesday, July 7th.

LENZ Therapeutics Stock Performance

Shares of LENZ Therapeutics stock traded down $0.04 on Friday, hitting $4.09. The company had a trading volume of 85,408 shares, compared to its average volume of 913,850. LENZ Therapeutics has a 1 year low of $4.01 and a 1 year high of $50.40. The stock has a 50 day moving average of $5.08 and a 200-day moving average of $7.36. The stock has a market capitalization of $128.51 million, a price-to-earnings ratio of -1.00 and a beta of 0.66.

LENZ Therapeutics (NASDAQ:LENZ) last announced its earnings results on Tuesday, August 11th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.03. LENZ Therapeutics had a negative return on equity of 53.39% and a negative net margin of 586.74%.The company had revenue of $5.49 million for the quarter, compared to analysts’ expectations of $2.38 million. Equities analysts anticipate that LENZ Therapeutics will post -4.18 earnings per share for the current year.

Institutional Investors Weigh In On LENZ Therapeutics

Several large investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of LENZ Therapeutics during the 2nd quarter worth $13,019,000. Squarepoint Ops LLC grew its position in LENZ Therapeutics by 16.0% during the second quarter. Squarepoint Ops LLC now owns 1,747,096 shares of the company’s stock valued at $9,924,000 after buying an additional 240,597 shares during the period. Granahan Investment Management LLC increased its holdings in LENZ Therapeutics by 125.2% during the fourth quarter. Granahan Investment Management LLC now owns 431,100 shares of the company’s stock worth $6,898,000 after buying an additional 239,703 shares during the last quarter. C WorldWide Group Holding A S increased its holdings in LENZ Therapeutics by 40.0% during the first quarter. C WorldWide Group Holding A S now owns 700,000 shares of the company’s stock worth $6,405,000 after buying an additional 200,000 shares during the last quarter. Finally, Bank of America Corp DE raised its position in LENZ Therapeutics by 377.4% in the first quarter. Bank of America Corp DE now owns 547,534 shares of the company’s stock worth $5,010,000 after acquiring an additional 432,846 shares during the period. 54.32% of the stock is owned by hedge funds and other institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for people with presbyopia, an age-related condition that reduces the eye’s ability to focus on near objects. The company’s lead product is VIZZ (aceclidine hydrochloride ophthalmic solution), a prescription eye drop designed to improve near vision by creating a pinhole effect through pupil modulation while aiming to preserve distance vision.

In July 2025, the U.S. Food and Drug Administration approved VIZZ for the treatment of presbyopia in adults.